EarningsSvas Biosana delivered a solid 1Q 2025 with revenues of €32.7m (+14.3% YoY, +6.6% standalone), driven by recent acquisitions and strong momentum in the Balkans.
Expansion StrategyThe acquisitions of Hermes Pharma and Megapharm strengthen Svas Biosana's foothold in Serbia, enriching its product and client portfolios.
Financial PerformanceNet income reached €5.9m (+14.6% YoY), supported by effective cost control and easing raw material prices.